studying them in animals in the 20 years since it began studying antisense drugs. Even so, there is a push to identify new and better modifications, and many companies are converging on similar ones. This year, Isis plans to pick clinical candidates with bicyclic additions to the sugars in the nucleotides. With these modifications, nucleo tides are positioned such that basepairing becomes more stable, and potency is boosted, Crooke says. MDRNA of Bothell, Washington, acquired the patents for a similar technology, called bridged nucleic acids (BNAs), from Valeant Pharmaceuticals, headquartered in Aliso Viejo, California, this March. Both kinds of modification are similar to Locked Nucleic Acids, produced by Exiqon of Vedbaek, Denmark, and used by Santaris Pharma, which introduce a ring at the 2ʹ position of each sugar molecule. Such modifications increase the halflife by an order of magnitude compared with the types of oligonucleotide now in the clinic, says Santaris vice-president and chief scientific officer Henrik Ørum. "We inject these into animals systemically as naked molecules. Once they are in the tissues, they will have a half-life of weeks to many weeks. "
Santaris also focuses on making its singlestranded molecules as small as possible, to aid their entry to cells. RXi has also used this strategy, designing 15-nucleotide double-stranded molecules.
Another approach that is in development is to conjugate antibodies or other specific targeting agents directly to the RNA molecules. Biotechnology company Dicerna Pharmaceuticals in Watertown, Massachusetts, is working with 27-nucleotide sequences, based on their proprietary Dicer Substrate Technology, which enter the RNAi-processing pathway earlier than other synthetic counterparts. It has partnered with Kyowa Hakko Kirin, the biopharmaceutical arm of which is based in Princeton, New Jersey, to provide the delivery technology. But like many companies, Dicerna is interested in multiple delivery strategies. The rise of RNAi therapeutics companies has spurred the development of additional technology to track how oligo nucleotides are processed by the body, but high-throughput purification and analysis technologies are not designed for such large molecules with a strong negative charge. Researchers who want to track nucleic-acid metabolites from humans and animals have a "huge problem", says Michael McGinley, bioseparations product manager for Phenomenex in Torrance, California. "You have polar [charged] oligonucleotides floating around in serum that like to bind to things. How are you going to pull them and their metabolites out and separate them from everything else that's there?" In September of last year, Phenomenex began selling kits and other products, such as its Clarity Oligo-MS and Clarity Oligo-RP chromatography columns, to researchers who are running preclinical and clinical studies. These kits provide highthroughput techniques to isolate synthetic oligo nucleotides from biological fluids such as serum and urine, as well as from solid tissues, including liver and lung tissue. Although McGinley anticipates tweaking and improving the products over time, he says that they work well with all of the delivery devices, conjugates and modifications tested so far.
